文献速递临床试验与 GCP医学人工智能与信息学新药、器械与细胞基因治疗研发

阿片成瘾药物辅助治疗联合移动健康干预的效果:随机临床试验研究方案

The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
PubMed 文献 · Trials · 2016-12-12

本研究为一项非盲随机临床试验方案,计划将440例符合阿片使用障碍诊断且严重程度至少为中度的患者随机分配至药物辅助治疗(MAT)联合A-CHESS智能手机干预组或单纯MAT组,随访24个月,主要结局为两组在24个月内非法阿片使用天数百分比的差异,同时评估其他物质使用、生活质量、治疗保留、卫生服务利用及HIV和HCV相关指标。

要点

  • 440例阿片使用障碍患者随机接受MAT+A-CHESS或单纯MAT,随访24个月。
  • 主要结局为24个月内非法阿片使用天数百分比的组间差异。
  • A-CHESS组使用智能手机16个月,所有患者在基线及第4、8、12、16、20、24个月评估。

核心结论

  • A-CHESS已被证明可改善酒精依赖患者的康复,本研究旨在检验其联合MAT对阿片依赖患者的效果及可及性。

研究设计与样本

  • 非盲随机临床试验,计划随机分配440例符合阿片使用障碍诊断且严重程度至少为中度的患者,接受MAT+A-CHESS或单纯MAT。
  • A-CHESS组患者使用智能手机16个月,所有患者随访24个月。
  • 在基线及第4、8、12、16、20、24个月通过20至30分钟电话调查收集数据,基线及此后每月最多两次尿液筛查。

主要发现

  • 主要结局为两组在24个月干预期间非法阿片使用天数百分比的差异。
  • 次要结局包括其他物质使用、生活质量、治疗保留、卫生服务利用,以及HIV和HCV相关的筛查和检测率、药物依从性、风险行为和照护链接的组间差异。
  • 将分析MAT+A-CHESS效应的中介因素和调节因素。

关键数值与推荐

  • 纳入标准为符合阿片使用障碍诊断且严重程度至少为中度,并正在接受美沙酮、注射用纳曲酮或丁丙诺啡治疗。
  • 使用混合效应模型评估主要和次要结局,基线评分作为协变量,治疗条件作为受试者间因素,结局反映六个时间点各评估的评分。
  • 每个结局分别进行分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opioid dependence has devastating and increasingly widespread consequences and costs, and the most common outcome of treatment is early relapse. People who inject opioids are also at disproportionate risk for contracting the human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study tests an approach that has been shown to improve recovery rates: medication along with other supportive services (medication-assisted treatment, or MAT) against MAT combined with a smartphone innovation called A-CHESS (MAT + A-CHESS). METHODS/DESIGN: This unblinded study will randomly assign 440 patients to receive MAT + A-CHESS or MAT alone. Eligible patients will meet criteria for having an opioid use disorder of at least moderate severity and will be taking methadone, injectable naltrexone, or buprenorphine. Patients with A-CHESS will have smartphones for 16 months; all patients will be followed for 24 months. The primary outcome is the difference between patients in the two arms in percentage of days using illicit opioids during the 24-month intervention. Secondary outcomes are differences between patients receiving MAT + A-CHESS versus MAT in other substance use, quality of life, retention in treatment, health service use, and, related to HIV and HCV, screening and testing rates, medication adherence, risk behaviors, and links to care. We will also examine mediators and moderators of the effects of MAT + A-CHESS. We will measure variables at baseline and months 4, 8, 12, 16, 20, and 24. At each point, patients will respond to a 20- to 30-min phone survey; urine screens will be collected at baseline and up to twice a month thereafter. We will use mixed-effects to evaluate the primary and secondary outcomes, with baseline scores functioning as covariates, treatment condition as a between-subject factor, and the outcomes reflecting scores for a given assessment at the six time points. Separate analyses will be conducted for each outcome. DISCUSSION: A-CHESS has been shown to improve recovery for people with alcohol dependence. It offers an adaptive and extensive menu of services and can attend to patients nearly as constantly as addiction does. This suggests the possibility of increasing both the effectiveness of, and access to, treatment for opioid dependence. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02712034 . Registered on 14 March 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gustafson DH, Landucci G, McTavish F, et al. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials. 2016. PMID: 27955689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。